ATE529536T1 - Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen - Google Patents

Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen

Info

Publication number
ATE529536T1
ATE529536T1 AT06840081T AT06840081T ATE529536T1 AT E529536 T1 ATE529536 T1 AT E529536T1 AT 06840081 T AT06840081 T AT 06840081T AT 06840081 T AT06840081 T AT 06840081T AT E529536 T1 ATE529536 T1 AT E529536T1
Authority
AT
Austria
Prior art keywords
identifying
treating individuals
complex karyotypes
individuals showing
showing complex
Prior art date
Application number
AT06840081T
Other languages
English (en)
Inventor
Charles Sawyers
Francis Lee
Neil Shah
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE529536T1 publication Critical patent/ATE529536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06840081T 2005-12-01 2006-11-30 Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen ATE529536T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74128005P 2005-12-01 2005-12-01
PCT/US2006/061399 WO2007065124A2 (en) 2005-12-01 2006-11-30 Methods of identifying and treating individuals exhibiting complex karyotypes

Publications (1)

Publication Number Publication Date
ATE529536T1 true ATE529536T1 (de) 2011-11-15

Family

ID=37907170

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06840081T ATE529536T1 (de) 2005-12-01 2006-11-30 Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen

Country Status (5)

Country Link
US (1) US20090197893A1 (de)
EP (1) EP1960546B1 (de)
AT (1) ATE529536T1 (de)
ES (1) ES2372975T3 (de)
WO (1) WO2007065124A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202950B2 (en) * 2006-04-07 2012-03-22 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP2327793A1 (de) * 2009-11-25 2011-06-01 Universität Zu Köln Pyrosequenzierungsverfahren zur Vorhersage der Reaktion eines Patienten auf eine Antikrebsbehandlung
JP5940771B2 (ja) * 2010-07-12 2016-06-29 アークレイ株式会社 ａｂｌ遺伝子多型の検出用プローブおよびその用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1169038E (pt) * 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
KR20070094956A (ko) * 2005-01-05 2007-09-27 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 약-내성 증식성 질병의 치료
WO2007014250A2 (en) * 2005-07-26 2007-02-01 Vertex Pharmaceuticals Incorporated Abl kinase inhibition

Also Published As

Publication number Publication date
WO2007065124A2 (en) 2007-06-07
WO2007065124A3 (en) 2007-07-05
ES2372975T3 (es) 2012-01-30
US20090197893A1 (en) 2009-08-06
EP1960546B1 (de) 2011-10-19
EP1960546A2 (de) 2008-08-27

Similar Documents

Publication Publication Date Title
CY1123503T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MX2008009886A (es) Anticuerpos que enlazan par-2.
ATE526987T1 (de) Dr5-antikörper und deren verwendung
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
EP1784639A4 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE602005021766D1 (de) Verfahren zur behandlung von atherosklerose
ATE529536T1 (de) Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties